Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared a post on LinkedIn about a paper by published in Nature Reviews Cancer:
“ADCs biology is shaped by antibody, linker stability, payload, and immune synergy
- Systemic kinetics: DAR balance critical; high DAR – higher clearance/toxicity, low DAR – weak efficacy
- Linker chemistry controls payload release: cleavable vs non-cleavable, stability/efficacy vs bystander effects
- Fc effector functions = ADCC, ADCP, TAM processing – can enhance efficacy but add toxicity
- Immunogenic cell death (ICD): payloads trigger DAMP release – DC maturation and CD8⁺ T cell priming
- Payload innovation: beyond chemo-degraders, immune activators, protein modulators.”
Title: Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
Authors: Alfred Zippelius, Sara M. Tolaney, Paolo Tarantino, Joseph P. Balthasar, Greg M. Thurber
You can read the Full Article in Nature Reviews Cancer.
More posts featuring Jean-Charles Soria.
